Literature DB >> 18721875

Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation.

Martin Körber1, Roland Bodmeier.   

Abstract

The incorporation of the model protein hen egg white lysozyme into liquid in situ forming poly(lactide-co-glycolide) (PLGA) implant or microparticle formulations was investigated. Ternary solvent blends of dimethyl sulfoxide (DMSO), ethyl acetate and water were used to adjust the protein solubility in order to facilitate the incorporation of either dispersed or dissolved protein into the polymer solution. Lysozyme formed large gel particles when dispersed directly in the polymer solution. These formulations had a pronounced initial release. Non-aqueous precipitation of lysozyme from solutions in DMSO with ethyl acetate led to a reversible aggregation without loss in biological activity. Lysozyme could be incorporated in a finely dispersed state through an in situ precipitation by non-solvent or polymer addition. Non-aqueous precipitation could thus be utilized to manufacture biodegradable in situ forming drug delivery systems containing homogeneously distributed and bioactive protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721875     DOI: 10.1016/j.ejps.2008.07.007

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

1.  One-step electrohydrodynamic production of drug-loaded micro- and nanoparticles.

Authors:  Marjan Enayati; Zeeshan Ahmad; Eleanor Stride; Mohan Edirisinghe
Journal:  J R Soc Interface       Date:  2009-10-14       Impact factor: 4.118

2.  PEGylation to Improve Protein Stability During Melt Processing.

Authors:  Parker Lee; Jenna Towslee; João Maia; Jonathan Pokorski
Journal:  Macromol Biosci       Date:  2015-06-12       Impact factor: 4.979

3.  Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion.

Authors:  Zahra Ghalanbor; Martin Körber; Roland Bodmeier
Journal:  Pharm Res       Date:  2009-12-23       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.